MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

Inclusion Criteria:

- Male or female participants greater than or equal to (>=) 18 years old with a clinical
diagnosis of stable moderate to severe plaque psoriasis (defined by Psoriasis Area and
Severity Index [PASI] score >=12, Physician Global Assessment [PGA] score >=3, and
>=10% of body surface area affected at Screening and Baseline [Day 1 of Week 1]) who
have a history of receipt of or are candidates for systemic therapy or phototherapy
for active plaque-type psoriasis despite topical therapy

- Participants must not have received more than 1 biologic therapy

- Other protocol-defined inclusion criteria could apply

Exclusion Criteria:

- Participants was excluded if they have erythrodermic, pustular, guttate, or
medication-induced forms of psoriasis or other active skin diseases/infections that
may interfere with the evaluation of plaque psoriasis

- Participants must not have received adalimumab or an investigational or licensed
biosimilar of adalimumab; topical therapies for the treatment of psoriasis or
ultraviolet B phototherapy within 2 weeks of investigational medicinal product (IMP)
administration or plan to take such treatment during the trial; or psoralen combined
with ultraviolet A phototherapy or nonbiological systemic therapies for psoriasis
within 4 weeks prior to IMP administration

- Participants was excluded if they have a history of an ongoing, chronic, or recurrent
infectious disease (except for latent tuberculosis [TB]); history of active TB; or a
history of hypersensitivity to any component of the IMP formulation, comparable drugs,
or latex

- Other protocol-defined exclusion criteria could apply